Industry Reports
The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
The ultimate guide to the complex web of interactions within the U.S. prescription distribution and reimbursement system more >
The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
The most comprehensive tool for analyzing the economic and business realities of the U.S. pharmaceutical distribution industry. more >
From The Drug Channels Blog
Tuesday, August 18, 2026
REMS Removed: Why CAR-T’s Expansion into Community Oncology Could Benefit the Big Three Wholesalers
By Greis Kapexhiu and Adam J. Fein, Ph.D. In June 2025, the FDA announced that CAR-T therapies would no longer be subject to a REMS program. more >
Friday, August 14, 2026
Hub Transitions Need Proven Plans, Smart Scale-Up
Today's guest post comes from Josh Marsh, Vice President and General Manager at Cardinal Health Sonexus™ Access and Patient Support. Josh examines the risks manufacturers take more >
